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Heterogeneity of miR-10b 
expression in circulating tumor 
cells
Christin Gasch1,*, Prue N. Plummer1,*, Lidija Jovanovic2,3, Linda M. McInnes4, 
David Wescott1, Christobel M. Saunders4, Andreas Schneeweiss5,6, Markus Wallwiener5,6, 
Colleen Nelson2,3, Kevin J. Spring7,8, Sabine Riethdorf9, Erik W. Thompson3,10, Klaus Pantel9 
& Albert S. Mellick1,11,*
Circulating tumor cells (CTCs) in the blood of cancer patients are recognized as important potential 
targets for future anticancer therapies. As mediators of metastatic spread, CTCs are also promising 
to be used as ‘liquid biopsy’ to aid clinical decision-making. Recent work has revealed potentially 
important genotypic and phenotypic heterogeneity within CTC populations, even within the same 
patient. MicroRNAs (miRNAs) are key regulators of gene expression and have emerged as potentially 
important diagnostic markers and targets for anti-cancer therapy. Here, we describe a robust in situ 
hybridization (ISH) protocol, incorporating the CellSearch® CTC detection system, enabling clinical 
investigation of important miRNAs, such as miR-10b on a cell by cell basis. We also use this method 
to demonstrate heterogeneity of such as miR-10b on a cell-by-cell basis. We also use this method to 
demonstrate heterogeneity of miR-10b in individual CTCs from breast, prostate and colorectal cancer 
patients.
Circulating tumor cells (CTCs) have been demonstrated to be an independent prognostic marker of 
clinical outcome in patients with solid tumors1–3. Numerous assays for the enrichment and detection 
of CTCs have been developed and used, however the semi-automated CellSearch® system (Veridex, 
Raritan, NJ, USA) remains the only device cleared by the Food and Drug Administration (FDA) for 
clinical use in metastatic breast, prostate and colon cancer4,5. To date, little is known about phenotypic 
characteristics of clinically significant CTCs capable of establishing metastasis at secondary sites, or the 
functional significance of CTC heterogeneity6,7. As a link between the primary tumor and the forma-
tion of metastasis throughout the body, CTCs are not only a promising target for future anti-metastasis 
therapeutic strategies, but can also be analyzed via a ‘liquid biopsy’ that can be obtained by a simple 
blood draw4,8. Furthermore, CTC analysis enables continuous monitoring of patient condition during 
the clinical course of their disease allowing early detection of recurrence and monitoring response to 
treatment5,8. However, the number of CTCs can be very small; as few as one CTC in 109 peripheral 
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blood mononuclear cells (PBMNCs). This rarity makes the enrichment, detection and analysis of CTCs 
challenging4,5,8. Molecular analysis of cell fractions enriched for CTCs [e.g. after epithelial cell adhesion 
molecule (EpCAM) enrichment] often face the problem of an over-representation of leukocytes, making 
data obtained by bulk CTC isolation protocols difficult to interpret8,9. Moreover, small but clinically 
significant subpopulations are often missed during routine analysis of primary tumor biopsies4,6,10,11, 
and only a few CTCs are capable of extravasating into surrounding tissue and growing as a metastasis 
at a secondary site6,7. These cells give important clues as to the genotypic and phenotypic changes that 
enable metastasis and ultimately patient death. Thus, collective analysis of individual CTCs is the most 
promising way of overcoming these critical issues and improving the utility of CTC analysis.
MiRNAs function as post-transcriptional regulators of gene expression and mediate a range of path-
ways linked to disease and development12,13. Several miRNAs, such as miR-10b have been directly linked 
to the epithelial-mesenchymal transition (EMT)12–14 and metastasis in breast and prostate cancer15–18. 
Furthermore, increased expression of miR-10b has been demonstrated in glioma, as well as metastatic 
pancreatic cancers19,20. Notably, increased miR-10b blood serum levels have been described in gastric 
cancer, non-small lung cancer and metastatic breast cancer18,21,22. However, as there is no association 
between miR-10b levels in the primary tumor and metastasis the link between miR-10b and metastasis 
remains controversial. It has been suggested that miR-10b may have a biological effect on a few cells at 
the leading edge of the tumor, or a small number of cancer cells shed into the blood23.
For analysis of cell-based miRNA expression ISH protocols using locked-nucleic acid (LNA) probes 
have been developed and applied to cell preparations, fresh frozen tissue and paraffin embedded tis-
sues24–26. To enable the detection of miR-10b in distinct cell types present in a complex cellular environ-
ment such as CTCs in peripheral blood we have adapted current ISH protocols, combined with antibody 
based immunofluorescence (IF), to be used with the CellSearch® CTC detection system (Fig. 1). Using 
this protocol we demonstrate miR-10b heterogeneity in CTCs isolated from the blood of metastatic 
cancer patients for the first time.
Results
MiR-10b expression in cancer cell lines. To identify suitable cells for method development and 
evaluation, commercially available breast cancer (MCF-7 and MDA-MB-231) and colorectal cancer 
(HCT-116 and SW480) cells were analyzed for miR-10b expression by ISH (Fig. 2). MiR-10b expression 
was detected in all cell lines. Notably, a slightly increased expression of miR-10b could be detected in the 
highly metastatic MDA-MB-231 cells and SW480 cells compared to less metastatic MCF-7 and HCT-116 
cells, respectively.
Spike experiment using MCF-7 and MDA-231 cells. To adapt the ISH procedure for analyzing 
CTCs detected in the blood of cancer patients with the CellSearch® system, spiking experiments using 
blood of a healthy volunteer donor were performed. MDA-MB-231 and MCF-7 cells were spiked into 
7.5 ml of blood from the healthy donor (for miR-10b probe). Additionally, two blood samples were 
spiked with MCF-7 cells to be used as positive (U6 probe) and negative control (scrambled probe). All 
samples were processed with the CellSearch® system, screened with the CellTracks® Analyzer to identify 
CK+ DAPI+ CD45− tumor cells and fixed in the CellSearch® cartridge. The combined ISH/IF protocol 
was applied using either miR-10b, U6-positive or scrambled-negative probes with IF staining using anti-
bodies from the CellSearch® Epithelial Cell Kit (Veridex). CTC image analysis was performed directly in 
the CellSearch® cartridge using IF microscopy. MCF-7 cells and MDA-MB-231 cells could be detected 
and analyzed for miR-10b expression. As observed in previous cell line experiments MDA-MB-231 cells 
revealed a high miR-10b expression in comparison to the moderate miR-10b expression in MCF-7 cells 
(Fig.  3). No signal was detected with the scrambled-negative control probe, and strong positive signal 
was observed with the U6-positive probe. Cell loss during re-fixation and ISH procedure was found to be 
minimal (~1%) for freshly processed samples (within 48 h after fixation) determined by re-enumeration 
of spiked MCF-7 cells after ISH analysis (134 of 135 cells detected with the CellSearch®).
MiR-10b heterogeneity in CTCs from cancer patients. To investigate miR-10b expression in 
CTCs in the blood of cancer patients, cells collected from 11 metastatic cancer patients (eight breast 
cancer, two prostate cancer and one colorectal cancer patient), were analyzed using the combined ISH/IF 
in cartridge protocol. MiR-10b positive (miR-10b+ ) as well as miR-10b negative (miR-10b−) CTCs could 
be detected in 10 of 11 patients (Figs 4 and 5a). One breast cancer patient (Breast 2) presented with 19 
miR-10b+ CTCs only. The abundance of miR-10b+ CTCs in the analyzed CTC population of these 11 
patients was 67% in the colorectal cancer patient, 40% and 20% in the prostate cancer and ranged from 
20-94% (mean: 67%) in the breast cancer patients (Fig. 5a).
For semi-quantitative analysis of miR-10b expression in individual CTCs we established a miR-10b 
immunoscoring (Fig.  5b). Except for one breast cancer patient (Breast 2) with only miR10b+ CTCs, 
expression levels among CTC populations varied from ‘negative (0)’ to ‘strong (+ 3)’ in all patients 
(Supplementary Table S1).
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Cell losses during the fixation and ISH procedure were exemplarily determined by re-enumeration 
of CTCs from five patients that initially presented with a total number of less than 100 CTCs. In these 
samples an average cell loss (± SEM) of 24.9 ± 7.6% (range: 0–55.8%), varying with length of storage 
prior ISH analysis and sample quality, was observed.
The application of our combined ISH/IF protocol for analyzing CTCs proved to be a robust method 
which revealed a heterogeneous distribution of miR-10b expression among CTCs from the same patient, 
across three different epithelial tumor types.
Discussion
In this study, we describe a novel, robust combined ISH and IF protocol that enables expression analysis 
of microRNAs in definite cell types, such as CTCs. Using tumor cell line spiking experiments we adapted 
the protocol to be used on CTCs after being detected with the CellSearch® CTC detection system. As 
a proof-of-principle the expression of miR-10b was investigated in 511 CTCs isolated from metastatic 
cancer patient with different epithelial tumor types (breast, colorectal and prostate cancer) revealing a 
heterogeneous miR-10b expression pattern in the CTC populations.
For method development we performed ISH on MCF-7 and MDA-MB-231 breast and HCT-116 and 
SW480 colon cell line cell preparations, detecting moderate but clear miR-10b expression in MCF-7 and 
HCT-116 and a high expression in MDA-MB-231 and SW480 cells. This expression pattern is consistent 
with previous miRNA expression studies in cancer cell lines using qPCR and array-based technologies27.
Figure 1. Schematic representation of the combined ISH/IF procedure. The three day stepwise protocol 
for analysis of CTCs detected with the CellSearch® system. CTC enrichment and staining initially occurs 
using the CellSearch®. CTCs are then enumerated using the CellTracks® Analyzer and fixed in the 
CellSearch® cartridge. The ISH/IHC protocol using LNA probes proceeds in cartridge, followed by manual 
visualization of miR expression in CTCs on a cell-by-cell basis. DIG labelled probes detected with FITC 
labelled anti-DIG antibody allowed visualisation and localization of miR expression in cells, which are also 
re-labelled with cell specific, CTC identifying antibodies from the Circulating Epithelial Cell Kit (Veridex). 
CTCs can then be labelled as either miR+, CK+, DAPI+ and CD45−; or miR−, CK+, DAPI+ and CD45−, in a 
semi-quantitative way.
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Though various ISH protocols for the analysis of messenger RNA (mRNA) have been described pre-
viously28–30 the analysis of miRNA expression is less common and requires specified adaptions24–26. In 
particular, the use of locked-nucleic-acid incorporated DNA probes enhances the hybridization efficiency 
and thus improves the detection of small miRNA molecules31. Several recent methods, have adapted tra-
ditional ISH for the analysis of miRNAs24–26. These protocols generally use LNA probes in combination 
with single spectrum (colorimetric or fluorescence) detection technologies, applied to formalin fixed 
paraffin embedded (FFPE) or fresh frozen tissues25,26 or preparations of cultured cells28. By combining 
ISH with IF our technique enables the analysis of specific cell subpopulations in heterogeneous tissue 
or cell preparation (e.g. CTCs surrounded by normal blood cells). Unlike other ISH protocols24,25,29, 
our protocol includes a short hybridization step only, enabling the procedure to be performed in one 
day. Moreover, the inherent stability across the steps allows periods of convenient storage and shipping 
between different sites of analysis.
Based on the heterogeneity of CTCs described previously4,11 and their prominent role in the metas-
tasis, molecular characterisation of individual CTCs is an emerging research field. Variations in the 
expression of specific proteins, as well as a heterogeneous distribution of gene amplifications/mutations 
Figure 2. MiR-10b expression analysis in breast and colorectal cancer cell lines by ISH. Higher 
expressions levels of miR-10b in MDA-MB-231 cells compared with MCF-7 breast cancer cells and in 
SW480 compared with HCT-116 colorectal cancer cells. Cells were stained with miR-10b as well as 
scrambled= negative and U6-positive control probes. Nuclei were visualized with DAPI (blue). Resolution 
40× . Scale bars, 20 μ M.
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have been observed in several studies. For example, human epidermal growth factor receptor 2 (HER2) 
and epidermal growth factor receptor (EGFR) expression patterns were analyzed in CTCs detected with 
the CellSearch® system in metastatic breast and colon cancer patients respectively4,32. Genotypic heter-
ogeneity regarding gene mutations (e.g. in p53, KRAS, PIK3CA) and gene amplifications (e.g. EGFR, 
HER2, leucine-rich g-protein receptor 5, Aurora A kinase and androgen receptor) could be observed in 
individual CTCs from colon4,11, breast6 and prostate cancer patients33. Recently, Raemskoeld et al. estab-
lished a protocol enabling full-length mRNA sequencing of single cells and performed mRNA expression 
profiling in single CTCs from a melanoma patient34. Our protocol is the first to enable the down-stream 
analysis of individual CTCs for microRNA expression. The only other study addressing microRNA anal-
ysis in CTCs of Sieuwerts et al. was performed on bulk CTCs after being processed using the CellSearch® 
Profile Kit (Veridex) and procedure9. Unlike the CellSearch® Epithelial Cell Kit this procedure includes 
the EpCAM enrichment only, resulting in an EpCAM-enriched cell fraction containing all CTCs and 
numerous remaining leukocytes. Though demonstrating the feasibility of CTC-associated microRNA 
profiling in a leukocyte-rich background, information regarding the distribution of miRNA expression 
in individual CTCs and also about the localization of the miRNA expression are not provided.
Using our technique we detected heterogeneous miR-10b expression in CTCs from patients with 
metastatic breast, prostate and colon cancer, respectively. MiR-10b expression has been described by Ma 
et al. and others to be linked to EMT and metastasis in breast cancer15,16,18. First studies also emphasize 
a role of miR-10b in colorectal and prostate cancer malignancy17,23,35,36. However, work from Gee et al. 
could not confirm the correlation of miR-10b expression in human breast tumors with metastasis and 
progression23, suggesting that only small highly malignant subpopulations of the primary tumor to be 
miR-10b positive. In this context, the detection of miR-10b+ CTCs, as putative founders of metastatic 
outgrowth, is an important finding that emphasizes the importance of miR-10b in cancer malignancy 
and provides avenues for further research in this field.
Figure 3. MiR-10b ISH analysis of breast cancer cell lines captured by the CellSearch® system. MiR-10b+ 
CK+ DAPI+ MCF-7 and MDA-MB-231 cells (white arrows) spiked into blood, captured by the CellSearch® 
system and identified by image analysis. Also shown are miR-10b− CK− DAPI+ (red arrows) and miR-10b+ 
CK− DAPI+ (yellow arrows) cells detected by IF microscopy. Also shown are the results U6-positive and 
scrambled-negative control probe analysis, respectively. Nuclei were visualized with DAPI. Resolution 40× . 
Scale bars, 20 μ M.
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Conclusion
Our protocol incorporates ISH with fluorescent antibody detection that allows miRNA analysis of 
well-defined cell populations, such as CTCs in blood of cancer patients. This has the potential to be used 
for various other applications such as miRNA-profiling of endothelial or immune response cells in tissue 
sections. The protocol was adapted for microRNA analysis of individual CTCs detected from the blood 
Figure 4. MiR-10b expression analysis of CTCs from metastatic cancer patients by ISH. Shown, are miR-
10b+ CK+ DAPI+ CD45− CTCs and miR-10b− CK+ DAPI+  CD45− CTCs (white arrows) captured from 
the blood of metastatic breast, prostate and colorectal cancer patients. Nuclei were visualized with DAPI. 
Resolution 40×. Scale bars, 20μM.
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of cancer patients with the CellSearch® CTC detection system. Detecting CTCs with varying miR-10b 
expression and the crucial role of miR-10b in metastasis and disease progression points out the potential 
of our ISH protocol to be useful for identifying and studying clinically relevant CTC subpopulations.
Material and Methods
Cell lines. The human mammary carcinoma cell lines MCF-7 and MDA-MB-231 as well as colorectal 
cancer cells HCT-116 and SW480 were obtained from the American Type Culture Collection (ATCC) 
(Manassas, VA, USA). MCF-7 and MDA-MB-231 cells were maintained in DMEM, HCT-116 and SW480 
cells in RPMI medium (5% CO2, 37 °C). Cell medium was supplemented with 4.5 g/L glucose, 10% fetal 
bovine serum (FBS), 2 mM L-glutamine (Lonza, Basel, Switzerland), as well as 10 U/mL penicillin, and 
10 μ g/mL streptomycin (Life Technologies, Carlsbad, CA, USA). For ISH analysis cells were either grown 
on chamber slides (Thermo Fisher Scientific, Waltham, MA, USA) or spiked into 7.5 mL of blood from a 
healthy donor that was subjected to the CellSearch® system (Veridex, Raritan, NJ, USA).
Patient samples. Blood from patients diagnosed with either metastatic breast, prostate cancer or 
colorectal cancer was collected at the Princess Alexandra Hospital, QLD, Australia, Royal Perth Hospital, 
WA, Australia, St John of God Subiaco Hospital, WA, Australia, or the University Hospital Heidelberg, 
Germany under protocols reviewed and approved by the respective Human Research Ethics Committees. 
For spiking experiments blood from a healthy volunteer was used. Written informed consent was obtained 
from all patients and the healthy volunteer. Patients were chosen based on their clinical diagnosis of late 
stage metastatic disease.
For CellSearch® analysis at least 7.5 mL of blood were drawn into a CellSave® tube (Veridex) and 
stored at ambient temperature until processing (within 96 h after blood sampling).
Locked nucleic acid (LNA) probes. ISH was performed using 5′ and double digoxigenin (DIG) con-
jugated miCURY LNA detection probes from Exiqon (Vedbæk, Denmark): (i) a U6-small nuclear RNA 
(positive) probe: CACGAATTTGCGTGTCATCCTT; melting temperature (Tm): 84 °C; (ii) a scrambled 
(negative) probe: GTGTAACACGTCTATACGCCCA; Tm:87 °C; and (iii) a specific anti-miR-10b probe: 
CACAAATTCGGTTCTACAGGGTA; Tm:83 °C. For hybridization the following final concentrations of 
probe were used: U6-positive (10 nM), scrambled-negative (40 nM) and miR-10b (40 nM).
ISH analysis of cancer cell lines. ISH analysis of cancer cell line cells was conducted to validate miR-
10b expression levels. Cells grown on chamber slides were prepared for analysis by washing: once with 
Figure 5. Heterogeneity of miR-10b expression in CTCs from metastatic cancer patients. (a) Distribution 
of miR-10b+ and miR-10b− CTCs in the analyzed CTC populations from eight breast, one colorectal and 
two prostate cancer patients. (b) Immunoscoring based on miR-10b signal intensity for semi-quantitative 
analysis of miR-10b expression. Shown are four CTCs from one prostate cancer patient: one miR-10b− 
(scoring: 0), and one with weak (+ 1), moderate (+ 2) and strong (+ 3) miR-10b expression. Nuclei were 
visualized with DAPI. Resolution 20× , Scale bars, 10 μ M.
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0.1% Triton X-100, PBS (10 min), and twice with PBS (10 min). They were then fixed (4% PFA, 5 min) 
and washed twice (PBS, 10 min) before blocking in hybridization buffer (50% formamide, 5 × SSC, 
1 × Denhardt’s solution, 0.5 mg/mL yeast tRNA, 0.5 mg/mL salmon sperm DNA) at 50 °C (10 min). 
Following blocking the buffer was replaced with hybridization buffer containing DIG labeled LNA probe, 
and the slides left to incubate (50 °C, 45 min). The slides were then subjected to three stringency wash 
steps: (i) twice with 0.1 × SSC (52 °C, 10 min); (ii) once with 2 × SSC (5 min); and (iii) three times with 
TN Buffer (0.1 M Tris-HCl pH7.5; 0.15 M NaCl) (3 min). Prior to antibody staining, the slides were 
incubated in antibody blocking buffer (1% blocking reagent, Roche Diagnostics, 10% FCS, 0.15 M NaCl, 
0.1 M Tris-HCL pH 7.5) for 30 min.
For probe detection cells were incubated in 1:400 diluted (in blocking buffer) anti-DIG-fluorescein 
(FITC)-Fab fragments (Roche Diagnostics, Basel, Switzerland) for 3 h. The slides were then washed: once 
with TNT buffer (1% Triton X-100 in TN-buffer, 5 min), and three times with TN buffer (3 min each). 
Cell nuclei were visualized using DAPI staining solution (1 ng/μ L DAPI, PBS, 5 min). Cells were then 
washed: (i) once with 0.1% Triton X-100/PBS (5 min); (ii) twice with PBS (10 min); and (iii) twice PBS 
(20 min). The slides were mounted in Prolong® Gold Antifade (Life Technologies, Carlsbad, California, 
USA). In this way slides can be stored at 4 °C for 2–4 days prior to microscopic analysis. The entire 
procedure was implemented in an RNAse-free working environment, with RNAse-free reagents. Unless 
otherwise stated steps were conducted at room temperature.
CTC detection using the CellSearch® system. CTC enrichment and detection with the 
semi-automated CellSearch® system using the Circulating Epithelial Kit (Veridex) was performed as 
described previously1,4,37. Blood (7.5 mL) from cancer patients, or blood from the healthy volunteer 
spiked with cancer cell line cells (MCF-7 and MDA-MB-231) was mixed with dilution buffer (6.5 mL) 
and centrifuged at 800 g (10 min) prior to loading the sample into the CellSearch® Autoprep system 
(Veridex). CTCs were immunomagnetically enriched using a ferrofluid-conjugated anti-EpCAM anti-
body (Veridex); and stained with 4′ ,6-Diamidin-2-phenylindol (DAPI), phycoerythrin (PE) conju-
gated anti-cytokeratin (CK) antibody and a Allophycocyanin (APC) conjugated anti-CD45 antibody as 
included in the Circulating Epithelial Cell Kit.
At the end of the run the enriched cell fraction (final sample volume approx. 350 μ L) was collected in 
the CellSearch® cartridge placed in a MagNest (Veridex) to direct EpCAM+ cells into a focal plane for 
microscopic analysis by the CellTracks® Analyzer (Veridex). CTCs were identified as CK+, DAPI+ and 
CD45− and by morphology (i.e. round to oval shape, high nucleus-to-cytoplasm ratio). The cartridge was 
not removed from the MagNest and the assembly was stored at 4 °C until fixation (within 24 h).
Cell fixation in the CellSearch® cartridge. To prepare cells for ISH analysis they were fixed directly 
in the CellSearch® cartridge38. The buffer in the cartridge was removed and replaced with 250 μ L meth-
anol:glacial acetic acid (3:1) solution. This was removed after 2 min, and replaced with another 250 μ L 
methanol:glacial acetic acid (3:1) solution. After another 2 min all liquid was carefully removed from 
the cartridge before it was dried using compressed air (10 min). The cartridge was removed from the 
MagNest and stored at 4 °C for up to three days or at − 20 °C for long-term storage prior to ISH analysis. 
All pipetting steps were performed with Mμ ltiflex pipette tips (PEQLAB, Erlangen, Germany).
Combined ISH and IF analysis in CellSearch® cartridge. Combined ISH and IF analysis was 
conducted directly in CellSearch® cartridges previously subjected to fixation (Fig.  1). Cartridges were 
filled with 0.1% Triton X-100, PBS. After 10 min it was replaced with PBS and left for another 10 min. 
Hybridization buffer (350 μ L) for blocking was added, and the cartridge left to incubate (30 min, 50 °C). 
Hybridization buffer containing LNA probes was then added, and the cartridge left to incubate for a 
further 45 min (50 °C). After hybridization cartridges were subjected to three stringency washes: (i) twice 
with 0.1× SSC (10 min, 52 °C); (ii) once with 2× SSC (5 min); and (iii) three times with TN Buffer (3 min 
each).
For LNA probe detection, and re-staining of antigens (CK and CD45), cells were blocked with anti-
body blocking buffer (30 min) and incubated (3 h) with 1:400 dilution of anti-DIG Fab fragments (Roche 
Diagnostics), as well as 1:6 dilution of CellSearch® antibody mixture (Cell Search Epithelial Cell Kit, 
Veridex,). The cartridge was then washed: (i) once with TNT buffer (5 min); and (ii) three times with 
TN buffer (5 min each). Cell nuclei were visualised with DAPI (1 ng/μ L in PBS, 5 min) and cells washed 
again: (i) once in 0.1% Triton X-100, PBS (10 min); (ii) four times with PBS (10 min). Cartridges were 
filled with PBS and stored at 4 °C for up to two days prior microscopic analysis. All pipetting steps were 
performed with Mμ ltiflex pipette tips (PEQLAB). Unless otherwise stated steps were conducted at room 
temperature.
Microscopic analysis. Imaging of cells grown on slides and of cells in the CellSearch® cartridges was 
performed on either a Zeiss LSM5 Live (Carl Zeiss, Jena, Germany) or an Olympus IX71 inverted fluores-
cence microscope (Olympus, Tokio, Japan). Image analysis was therefore conducted using the AxioVison 
Rel. 4.8 Imaging software (Carl Zeiss) or OlyVia ver. 2.8. Imaging software (Olympus), respectively.
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